Winner Medical(SZ:300888) CMS·2025-05-03 06:16Investment Rating - The report maintains a strong buy investment rating for the company [3][10]. Core Views - The company's revenue is projected to grow by 9.7% year-on-year to 8.98 billion yuan in 2024, with the consumer goods segment growing by 17% to 4.99 billion yuan and the medical segment growing by 1% to 3.91 billion yuan [1][10]. - In Q1 2025, revenue increased by 36.5% year-on-year to 2.6 billion yuan, with consumer goods and medical segments growing by 29% and 46% respectively [1][10]. - The company has implemented reforms in its consumer goods business, including organizational restructuring and marketing innovations, which are beginning to show positive results [1][10]. Financial Performance - In 2024, the company achieved a net profit of 700 million yuan, with a year-on-year growth of 19.8%, and a non-recurring net profit of 590 million yuan, growing by 43.4% [1][10]. - The company plans to distribute a total cash dividend of 379 million yuan for 2024, accounting for 54.43% of the net profit [1][10]. - The medical segment's revenue for 2024 is expected to be 3.91 billion yuan, with a growth of 1.1% [7][10]. Segment Analysis - The consumer goods segment is expected to achieve a revenue of 4.99 billion yuan in 2024, with a year-on-year growth of 17.1%, driven by products like cotton soft towels and sanitary napkins [2][7]. - The medical segment is projected to show steady growth, with high-end wound dressings performing particularly well, contributing to a revenue of 1.25 billion yuan in Q1 2025, a year-on-year increase of 46.3% [7][10]. Profitability and Valuation - The company's net profit margin improved to 7.75% in 2024, with an overall gross margin of 47.32% [10][16]. - The projected earnings per share (EPS) for 2025 is 1.81 yuan, with a price-to-earnings (PE) ratio of 28.9 [9][16]. - The company is expected to achieve a net profit of 1.05 billion yuan in 2025, reflecting a growth of 51% [9][10].